AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02286570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fastrach
Description: intubating laryngeal mask airway used for blind endotracheal intubation
Study NCT01330394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
Study NCT01330394 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
Study NCT04197102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Isolate
Description: A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
Study NCT04197102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBD Broad Spectrum
Description: A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
Study NCT04197102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
Study NCT00596128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of SOP
Description: SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
Study NCT02856607 — intervention group
Intervention type: OTHER
Intervention: determine the prognosis of threated patients according to the clinical care pathway.
Study NCT05081700 — intervention group
Intervention type: DRUG
Intervention: All patients in the study will be treated with ocrelizumab
Description: 300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
Study NCT02331550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative treatment
Description: Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
Study NCT02331550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant management
Description: Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
Study NCT04117672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: Active egg yolk powder
Study NCT04117672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo egg yolk powder
Description: Normal egg yolk powder
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: i.v. and oral
Study NCT01363752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: i.v. and oral
Study NCT01985087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
Study NCT01985087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
Study NCT04196413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD2 CAR T cells
Description: Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
Study NCT04196413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
Study NCT04196413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
Study NCT01993498 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: blood samples collection
Study NCT03638284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
Study NCT01083888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral
Study NCT00089778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 117-126:Fibroblast growth factor 5 (FGF-5)
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
Study NCT00089778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 5 (FGF-5):172-176/217-220
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
Study NCT00089778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
Study NCT02121015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share
Study NCT02121015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed
Study NCT02557932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
Study NCT02557932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy
Description: Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
Study NCT01646021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg once daily continuous (without interruption) by mouth for 21-day cycles
Study NCT01646021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
Study NCT03065764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 89Zr-Pembrolizumab
Description: eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab.
Study NCT01380717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-blocker, ACE-inhibitor
Description: Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
Study NCT01380717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers, ACE-Inhibitor
Description: Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
Study NCT03410407 — intervention group
Intervention type: OTHER
Intervention: Observation of CNS involvement
Description: AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
Study NCT01628653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-SMART
Description: 4-weeks' training
Study NCT02893982 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
Study NCT03784144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biering-Sorensen Test and Prone Plank Test
Description: All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
Study NCT03784144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biering-Sorensen Test and Prone Plank Test
Description: All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
Study NCT04062032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: ASA 81mg taken daily
Study NCT04062032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: ASA 325mg taken daily
Study NCT03760406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opti-VIM targeting in DBS surgery
Description: DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
Study NCT03355157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
Description: Drug intervention
Study NCT03355157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
Description: Drug intervention
Study NCT04507256 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
Study NCT04507256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to placebo will receive the same volume of solution as participants on active treatment.
Study NCT04998279 — intervention group
Intervention type: DRUG
Intervention: Granulocyte Colony-Stimulating Factor
Description: Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
Study NCT04998279 — intervention group
Intervention type: OTHER
Intervention: placebo
Description: mock test without injection of G-CSF
Study NCT02678767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
Study NCT02678767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
Study NCT00068380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00068380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02891239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay
Description: solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
Study NCT01901354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-tidal-volume ventilation
Description: Goal tidal volume is 6 cc/kg ideal body weight.
Study NCT00571558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Description: Given PO
Study NCT00571558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo photodynamic therapy
Study NCT00571558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01065493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QuitAdvisorMD Software Algorithm
Description: QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
Study NCT01065493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Counseling
Description: Standard Smoking Cessation Counseling
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 mg E4/3 mg DRSP
Description: a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg E4/6 mg DRSP
Description: a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg E4/12 mg DRSP
Description: a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
Study NCT02874248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75 mg E4/15 mg DRSP
Description: a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
Study NCT00540384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00540384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Description: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Study NCT01901354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Description: APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
Study NCT00622661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each
Study NCT00622661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each
Study NCT02683382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisturizing Eye Product in Liquid Formula
Description: Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
Study NCT02683382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing Eye Product in Liquid Formula
Description: Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
Study NCT03421314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate and/or Selenium yeast
Description: 30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
Study NCT00797628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decide2Quit
Description: Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
Study NCT00797628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Coach
Description: Control Patients will be referred by paper prescription to the control- Smoking Coach website.
Study NCT00893165 — intervention group
Intervention type: BEHAVIORAL
Intervention: moderate physical activity
Description: bed mounted cycles for physical activity for 30 min during each hemodialysis session
Study NCT03256058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinflation after early deflation
Description: the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
Study NCT03256058 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
Study NCT01639547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Ribavirin
Description: Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
Study NCT01639547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Ribavirin
Description: Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
Study NCT03628989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Technology
Description: If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
Study NCT01179841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playgroup
Description: The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
Study NCT01179841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training
Description: The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.